Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Association With Concomitant Diseases: Identification and Management

Chen, Yan; Tang, Xiangqi

doi:10.3389/fimmu.2022.890142

Cited by 5 publications

(4 citation statements)

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with A-CIDP in the setting of acute HBV tend to follow a monophasic disease course rather than the traditional relapsing-remitting or progressive chronic pattern [ 11 , 12 ]. This suggests acute HBV infection induces a distinct CIDP phenotype and clinical presentation.…”

Section: Discussionmentioning

confidence: 99%

Hepatitis B Precipitating Neurological Complications: A Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Conundrum

Krishnan,

Chandrasekar,

Natarajan

2024

Cureus

View full text Add to dashboard Cite

Hepatitis B virus stands as a prominent contributor to cirrhosis, hepatocellular carcinoma, and other liver-related fatalities. On the other hand, neurological manifestations in HBV-infected individuals are infrequently observed. Chronic inflammatory demyelinating polyneuropathy (CIDP) represents an immune-mediated neuropathy, known for its distinctive pattern of symmetrical involvement and weakness in both proximal and distal muscles. In this study, we present a noteworthy instance of chronic inflammatory demyelinating polyneuropathy (CIDP) occurring in a patient with chronic inactive hepatitis B infection.

show abstract

Section: Discussionmentioning

confidence: 99%

Hepatitis B Precipitating Neurological Complications: A Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Conundrum

Krishnan,

Chandrasekar,

Natarajan

2024

Cureus

View full text Add to dashboard Cite

show abstract

“…Anti-ganglioside antibodies have been described in 15-24% of patients with peripheral nervous system involvement in SLE. However, some studies did not show an association with antinuclear antibodies, anti-DNA antibodies, antiphospholipid antibodies, or low complement levels [6][7][8][9]. It is now understood that CIDP can be an autoimmune condition in its own, sharing certain HLA loci and common mechanisms with other autoimmune diseases [3].…”

Section: Discussionmentioning

confidence: 99%

Chronic Inflammatory Demyelinating Polyneuropathy as the Initial Presentation of Systemic Lupus Erythematosus Successfully Treated With Cyclophosphamide

Sastre Martínez,

Tróchez Ortiz,

Zuluaga Gómez

et al. 2024

Cureus

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is an autoimmune disorder that can manifest with a wide range of clinical features, including peripheral nervous system involvement. Among the neurological complications associated with SLE, chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare but significant entity. This case report explores the complex relationship between CIDP and SLE, emphasizing the challenges in diagnosis and the complexities of treatment strategies. We present the case of a patient diagnosed with CIDP as the initial manifestation of SLE, who exhibited a remarkable response to a unique treatment approach. This case underscores the potential overlap of these two conditions, the need for individualized diagnostic, and the importance of considering lupus activity when making therapeutic decisions. While conventional treatment approaches for CIDP are established, the management of CIDP in the context of SLE requires a thorough approach. This report presents a case where early intervention with steroids and cyclophosphamide yielded favorable outcomes, providing insights into alternative treatment options. As this subset of patients remains underrepresented in clinical trials, further research is needed to establish clear guidelines for the management of CIDP in SLE, optimizing patient care while minimizing risks associated with immunomodulatory therapies.

show abstract

“…The interpretation of nerve conducting study results is particularly difficult when the response amplitude is reduced below 1 mV in which case the presence of conduction blocks cannot be excluded. Incorrect technical as well as potential marker positioning can cause deviations in electroneurograph examinations [3,6,12].…”

Section: The Electrodiagnosismentioning

confidence: 99%

Molecular, Electrophysiological, and Ultrasonographic Differences in Selected Immune-Mediated Neuropathies with Therapeutic Implications

Dziadkowiak,

Nowakowska-Kotas,

Rałowska-Gmoch

et al. 2023

IJMS

View full text Add to dashboard Cite

The spectrum of immune-mediated neuropathies is broad and the different subtypes are still being researched. With the numerous subtypes of immune-mediated neuropathies, establishing the appropriate diagnosis in normal clinical practice is challenging. The treatment of these disorders is also troublesome. The authors have undertaken a literature review of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), Guillain–Barre syndrome (GBS) and multifocal motor neuropathy (MMN). The molecular, electrophysiological and ultrasound features of these autoimmune polyneuropathies are analyzed, highlighting the differences in diagnosis and ultimately treatment. The immune dysfunction can lead to damage to the peripheral nervous system. In practice, it is suspected that these disorders are caused by autoimmunity to proteins located in the node of Ranvier or myelin components of peripheral nerves, although disease-associated autoantibodies have not been identified for all disorders. The electrophysiological presence of conduction blocks is another important factor characterizing separate subgroups of treatment-naive motor neuropathies, including multifocal CIDP (synonyms: multifocal demyelinating neuropathy with persistent conduction block), which differs from multifocal motor neuropathy with conduction block (MMN) in both responses to treatment modalities and electrophysiological features. Ultrasound is a reliable method for diagnosing immune-mediated neuropathies, particularly when alternative diagnostic examinations yield inconclusive results. In overall terms, the management of these disorders includes immunotherapy such as corticosteroids, intravenous immunoglobulin or plasma exchange. Improvements in clinical criteria and the development of more disease-specific immunotherapies should expand the therapeutic possibilities for these debilitating diseases.

show abstract

Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Association With Concomitant Diseases: Identification and Management

Cited by 5 publications

References 102 publications

Hepatitis B Precipitating Neurological Complications: A Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Conundrum

Hepatitis B Precipitating Neurological Complications: A Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Conundrum

Chronic Inflammatory Demyelinating Polyneuropathy as the Initial Presentation of Systemic Lupus Erythematosus Successfully Treated With Cyclophosphamide

Molecular, Electrophysiological, and Ultrasonographic Differences in Selected Immune-Mediated Neuropathies with Therapeutic Implications

Contact Info

Product

Resources

About